Moreover, in clinical studies using the single p110δ-specific inhibitor Idelalisib, severe infections and infection-related fatal outcomes occurred [44] and warn against even more severe outcomes during long-term treatment with dual p110γ/δ inhibitors. This evidence concerns the gene PIK3CD and infection.